Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?

Cytokinetics, Incorporated CYTK recently announced additional results from ACACIA-HCM (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints in Adults with Non-Obstructive HCM) and MAPLE-HCM (Metoprolol vs Aficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM) studies.

The results were presented in a Late Breaking Clinical Session at the European Society of Cardiology Congress 2026 in Munich, Germany.

Additional analyses of ACACIA-HCM and MAPLE-HCM elaborate on the primary results from each study and expand the evidence base supporting the potential use of aficamten across the spectrum of HCM.

We note that CYTK obtained FDA approval of aficamten under the brand name Myqorzo in December 2025 for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM).

Strong initial uptake of the drug, along with Myqorzo’s expanding international presence, positions it as a meaningful commercial opportunity in the oHCM market.

CYTK is also looking to expand Myqorzo’s label.

More on CYTK’s ACACIA-HCM Study

ACACIA-HCM was a phase III, multi-center, randomized, double-blind, placebo-controlled study designed to evaluate the effect of aficamten compared to placebo in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).

Additional results from ACACIA-HCM demonstrate improvements in cardiac structure and diastolic function in patients with nHCM.

CYTK had earlier reported that ACACIA-HCM met both primary endpoints in symptomatic nHCM, showing statistically significant improvements in KCCQ Clinical Summary Score and maximal exercise performance (pVO2) versus placebo.

The additional ACACIA-HCM results suggest that aficamten’s benefits in nHCM may extend beyond improving exercise capacity and symptoms to reducing wall thickness and improving diastolic function. These findings provide further insight into how aficamten may benefit patients and highlight its potential as an important treatment option for nHCM, where no approved therapies currently exist.

Cytokinetics plans to submit a supplemental new drug application (sNDA) for aficamten in this indication in the fourth quarter of 2026. A potential approval in nHCM will expand the addressable market.

More on CYTK’s MAPLE-HCM Study     

MAPLE-HCM was a phase III, multi-center, randomized, double-blind active-comparator clinical trial of aficamten compared to metoprolol in patients with symptomatic oHCM.

As previously reported, the primary results of MAPLE-HCM demonstrated superiority of aficamten to metoprolol on pVO2. This post-hoc analysis evaluated the effects of aficamten and metoprolol on the primary and key secondary endpoints based on pre-trial medical therapy.

The new analysis of MAPLE-HCM showed that aficamten outperformed metoprolol across pre-trial treatment groups in patients with oHCM.

The FDA had earlier accepted CYTK’s sNDA for MAPLE-HCM, a phase III study of aficamten as monotherapy compared with metoprolol as monotherapy in patients with oHCM. The regulatory body assigned a target action date of Nov. 14, 2026.

Competition for CYTK’s Myqorzo

Myqorzo operates within an evolving treatment landscape for oHCM. Its primary branded competitor is Camzyos, a cardiac myosin inhibitor marketed by Bristol Myers Squibb BMY. In addition to this direct competition, Myqorzo faces established generic therapies, namely beta blockers and calcium channel blockers, which continue to serve as the first-line standard of care.

BMY obtained FDA approval for Camzyos in 2022 for the treatment of adults with symptomatic New York Heart Association class II-III obstructive HCM to improve functional capacity and symptoms.

The drug continues to gain traction in the targeted market, supported by growing demand and increased adoption among eligible patients.

The FDA accepted BMY’s supplemental new drug application seeking approval of Camzyos for the treatment of adolescents aged 12 to under 18 years with symptomatic oHCM.

A potential competitor for Cytokinetics is Edgewise Therapeutics, Inc. EWTX, which is advancing a cardiovascular pipeline targeting HCM, heart failure, and other cardiovascular and cardiometabolic conditions.

EWTX’s lead candidate, EDG-7500, is a novel, oral, selective cardiac sarcomere modulator currently being studied in a multipart phase II study in patients with oHCM and nHCM, with a phase III program targeted to be launched in the fourth quarter of 2026.

EWTX’s pipeline also includes EDG-15400 for heart failure. The company expects to initiate a phase II study on EDG-15400 in participants with heart failure with preserved ejection fraction in the second half of 2026.  

CYTK’s Price Movement, Valuation and Estimates

Cytokinetics’ shares have gained 12.4% year to date compared with the industry’s 8.7% growth.

Image Source: Zacks Investment Research

Going by the price/sales ratio, CYTK’s shares currently trade at 26.6X forward sales, higher than the industry’s average of 1.94X but lower than its mean of 49.08X.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for 2026 loss per share has narrowed to $6 from $6.26 over the past 60 days and the same for 2027 loss has narrowed to $4.54 from $4.59 over the same period.

Image Source: Zacks Investment Research

CYTK currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

 

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research